Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933230 | 1.00 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL12727370 | 0.81 | — | — | |
| SCHEMBL1644346 | 0.81 | — | — | |
| SCHEMBL1642831 | 0.81 | — | — | |
| SCHEMBL1642766 | 0.69 | — | — | |
| SCHEMBL14796722 | 0.69 | — | — | |
| SCHEMBL1643815 | 0.69 | — | — | |
| SCHEMBL1643275 | 0.65 | — | — | |
| SCHEMBL1643958 | 0.65 | — | — | |
| SCHEMBL1643870 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420694-B2 | Pyrrolidin-2-one derivatives as androgen receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2176220-B1 | Pyrrolidin-2-one derivatives as androgen receptor modulators | TAKEDA PHARMACEUTICAL (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-2176220-B1 | Pyrrolidin-2-one derivatives as androgen receptor modulators | TAKEDA PHARMACEUTICAL (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7834051-B2 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-16 | — | — | US | disclosed |
| US-7834051-B2 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-2176220-A2 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009020234-A2 | PYRROLIDIN-2 -ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042967-A1 | Cyclic amine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098336-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR | AR, NR5A1, SHBG | IRAK4 2754/4885 |
| US-20090042967-A1 | Cyclic amine compounds | SHBG, FSHR, ACP3 | IRAK4 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.